RxDoctor Payments Data

Loren Jones, MD

Urology · Austin, TXNPI 1235392911

Payments from drug & device makers

$54,779in general payments, 2019–2025

Across 113 payments — averaging $484.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calyxo, Inc.$49K
  • Boston Scientific$4K
  • AbbVie$315
  • Olympus America Inc.$292
  • Johnson & Johnson$198
  • Janssen Scientific Affairs, LLC$138
  • plus $1K from 27 others

What the payments were for

  • Speaking & faculty fees$3,69057%
  • Food & beverage$2,76943%
  • Education$150%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,779 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$567,200
Medicare patients
534
Services billed
13,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide129$1,810,517
Abiraterone Acetate91$272,255
OrgovyxRelugolix80$198,085
NubeqaDarolutamide12$144,062
MyrbetriqMirabegron40$42,556
GemtesaVibegron31$28,634
Silodosin69$6,021
Mirabegron ErMirabegron12$5,959
Tamsulosin Hcl389$5,504
Potassium Citrate ErPotassium Citrate24$5,122
Solifenacin Succinate138$4,716
Testosterone Cypionate61$3,500
Dutasteride64$2,041
Finasteride130$1,556
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst92$1,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$198$1,810,517129 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$138$272,25591 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$61$226,719111 claims
BayerNubeqa$29$144,06212 claims
Astellas Pharma US IncMyrbetriq$31$42,55640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.

Other urology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →